AngioDynamics, Inc. announced the commencement of the AMBITION BTK multicenter randomized controlled trial (RCT), which will ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent ...

Jan. 16, 2025 /PRNewswire/ -- Concept Medical Inc., a global pioneer in ... Controlled Trial of MagicTouch PTA – Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in the Treatment ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...